Eczema future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Eczema}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{Reflist|2}} ..." |
|||
| (4 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Eczema}} | {{Eczema}} | ||
{{CMG}}, {{AE}} [[User:Edzelco|Edzel Lorraine Co, D.M.D., M.D.]] | |||
==Overview== | |||
Future trends will focus more on [[genetic studies]] in [[eczema]]. <ref name="pmid22071473">{{cite journal| author=Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S | display-authors=etal| title=Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect. | journal=J Invest Dermatol | year= 2012 | volume= 132 | issue= 1 | pages= 98-104 | pmid=22071473 | doi=10.1038/jid.2011.342 | pmc=3236450 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22071473 }} </ref> | |||
==Eczema Future or Investigational Therapies== | |||
* Future trends will focus more on [[genetic studies]] in [[eczema]]. | |||
* These [[genetic discoveries]] can be applied to the development of new [[drugs]] that can target the [[molecular]] and [[physiological]] [[causes]] of the [[disease]], making an era of "personalized [[medicine]]". <ref name="pmid29217837">{{cite journal| author=Dugger SA, Platt A, Goldstein DB| title=Drug development in the era of precision medicine. | journal=Nat Rev Drug Discov | year= 2018 | volume= 17 | issue= 3 | pages= 183-196 | pmid=29217837 | doi=10.1038/nrd.2017.226 | pmc=6287751 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29217837 }} </ref> | |||
* [[Digitalization]] and [[artificial intelligence]] can also be applied to the [[management]] of [[eczema]]. <ref name="pmid33205485">{{cite journal| author=Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M | display-authors=etal| title=ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. | journal=J Eur Acad Dermatol Venereol | year= 2020 | volume= 34 | issue= 12 | pages= 2717-2744 | pmid=33205485 | doi=10.1111/jdv.16892 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33205485 }} </ref> | |||
==References== | ==References== | ||
Latest revision as of 00:12, 26 May 2022
|
Eczema Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Eczema On the Web |
|
American Roentgen Ray Society Images of Eczema |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Edzel Lorraine Co, D.M.D., M.D.
Overview
Future trends will focus more on genetic studies in eczema. [1]
Eczema Future or Investigational Therapies
- Future trends will focus more on genetic studies in eczema.
- These genetic discoveries can be applied to the development of new drugs that can target the molecular and physiological causes of the disease, making an era of "personalized medicine". [2]
- Digitalization and artificial intelligence can also be applied to the management of eczema. [3]
References
- ↑ Brown SJ, Kroboth K, Sandilands A, Campbell LE, Pohler E, Kezic S; et al. (2012). "Intragenic copy number variation within filaggrin contributes to the risk of atopic dermatitis with a dose-dependent effect". J Invest Dermatol. 132 (1): 98–104. doi:10.1038/jid.2011.342. PMC 3236450. PMID 22071473.
- ↑ Dugger SA, Platt A, Goldstein DB (2018). "Drug development in the era of precision medicine". Nat Rev Drug Discov. 17 (3): 183–196. doi:10.1038/nrd.2017.226. PMC 6287751. PMID 29217837.
- ↑ Wollenberg A, Christen-Zäch S, Taieb A, Paul C, Thyssen JP, de Bruin-Weller M; et al. (2020). "ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children". J Eur Acad Dermatol Venereol. 34 (12): 2717–2744. doi:10.1111/jdv.16892. PMID 33205485 Check
|pmid=value (help).